Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology

F. Roth-Walter, I. M. Adcock, C. Benito-Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz-Gracia, E. F. Knol, M. Jesenak, F. Levi-Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. C.A.M. Van Esch, C. Stellato*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune-driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence-related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for strategies aimed at disease prevention and supporting healthy aging.

Original languageEnglish
Pages (from-to)1089-1122
Number of pages34
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume79
Issue number5
Early online date18 Dec 2023
DOIs
Publication statusPublished - May 2024

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Funding

We thank the EAACI Executive Committee for funding this taskforce. The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy); FRW received funding from by Danube Allergy Research Cluster‐DARC #08 of the Karl‐Landsteiner University, Krems, Austria. GN received funding by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aim well Charitable Trust (UK), The Israel Science Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); RB received funding from the Austrian Science Fund FWF project SFB F4606‐B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); OP received funding from MICIIN (PID2020‐114396RB‐I00). MS has received research grants from the Swiss National Science Foundation (SNSF nr 310030_189334/1), GSK, Novartis and Stiftung vorm. Bündner Heilstätte Arosa.

FundersFunder number
Aim well Charitable Trust
Danube Allergy Research Cluster‐DARC
EAACI Executive Committee
Emalie Gutterman Memorial Endowed Fund
MICIINPID2020‐114396RB‐I00
Novartis and Stiftung
University of Salerno and Campania Region
GlaxoSmithKline
Medical Research CouncilMR/T010371/1
Engineering and Physical Sciences Research CouncilEP/T003189/1
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung310030_189334/1
FWF Austrian Science FundSFB F4606‐B28
Ministerio de Economía y CompetitividadCM17/00140, RD16/0006/0001
Ministero dell’Istruzione, dell’Università e della Ricerca2017MLC3NF_005
Israel Science Foundation
Instituto de Salud Carlos III
Università degli Studi di Messina
Regione Siciliana
European Academy of Allergy and Clinical Immunology

    Keywords

    • cell metabolism
    • immune senescence
    • immunometabolism
    • inflammaging
    • senolytic drugs
    • senomorphic drugs

    Fingerprint

    Dive into the research topics of 'Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology'. Together they form a unique fingerprint.

    Cite this